乾眼症市場：現況分析與預測（2024-2032）

Dry Eye Disease Market: Current Analysis and Forecast (2024-2032)

出版日期: 2024年07月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

由於乾眼症患者病率不斷上升、生物療法的進步以及意識和診斷的提高，乾眼症（DED）市場預計將以 4%左右的速度穩定成長。此外，新產品的推出是乾眼症治療市場成長的重要驅動力。一系列先進生物製劑、生物相似藥、創新口服療法和新療法的推出，大幅增加了治療乾眼症的選擇。這些市場發展不僅改善了患者的治療效果，還有助於顯著的市場擴張，為製藥公司和醫療保健提供者提供了充滿希望的機會。

依產品劃分，市場分為人工淚液、抗發炎藥、穿刺塞、促泌劑和其他產品。到2023年，人工淚液領域將佔據重要的市場佔有率，預計這一趨勢將在預測期內持續下去。人工淚液通常被用作預防 DED 的第一道防線，因為它們可以立即緩解乾燥、刺激和不適等症狀。醫療保健專業人員廣泛推薦針對不同程度乾眼症狀的患者使用人工淚液。它可以在櫃檯輕鬆購買且價格合理，已成為許多尋求快速緩解 DED 症狀的人的熱門選擇。

市場依通路分為醫院藥房、零售藥房和線上藥房。乾眼症市場由醫院藥局市場主導。老年人口的增加、高住院率和乾眼症的嚴重程度預計將推動這一領域的擴張。相反，零售藥房行業佔據乾眼症治療市場的第二大佔有率。

為了更了解乾眼症的市場介紹，市場分為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞太（中國、日本、印度等亞太地區）以及世界其他地區。在目前2023年的情況下，北美佔據市場主導地位。這一優勢可歸因於推動該地區乾眼症藥物需求和開發的多個因素，包括高可支配收入、先進的醫療基礎設施和不斷提高的意識。市場上營運的主要公司包括AbbVie Inc.、Alcon Inc.、Akorn、Johnson &Johnson、Bausch Health Companies Inc.、Horus Pharma、Mitotech、Novaliq GmbH、OASIS Medical、 Otsuka Pharmaceutical Co. Ltd.。

Dry Eye Disease (DED) is a common, frequently chronic, and frequently poorly controlled disease affecting millions of people. Since there is inadequate tear film on the outer surface of the eye, DED causes discomfort, and visual changes and may harm the surface of the eye if not treated. It is a complex disease that develops gradually in relation to the external environment and a person's lifestyle, and it depends on age, hormonal background, and other factors. Some of the market drivers include rising incidence of dry eye disease, development of new methods of management, and general awareness on the disease. For instance, as per the data of America Academy of Ophthalmology, approximately 20 million people in the United States are currently living with dry eye disease (DED), and that number is growing in both young and old adults. Further, about 250 million people are living with dry eye disease.

The Dry Eye Disease Market is expected to grow at a steady rate of around 4% due to rising prevalence of dry eye disease, advancements in biologic therapies, and increased awareness and diagnosis. Further, new product launches are a critical driver of growth in the dry eye disease treatment market. The introduction of advanced biologic therapies, biosimilars, innovative oral therapies, and a robust pipeline of emerging treatments are significantly enhancing the options available for managing dry eye disease. These developments not only improve patient outcomes but also contribute to the substantial expansion of the market, offering promising opportunities for pharmaceutical companies and healthcare providers.

Based on the Product, the market is segmented into Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogues, and Other Products. In 2023, the artificial tears segment held a significant share of the market, which is expected to persist during the forecast period. Artificial tears are commonly used as the first line of defense against DED due to their effectiveness in providing immediate relief from symptoms such as dryness, irritation, and discomfort. Artificial tears are widely recommended by healthcare professionals for patients with varying degrees of dry eye symptoms. Their easy accessibility over-the-counter and affordability make them a popular choice for many individuals seeking quick relief from DED.

Based on the distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The dry eye disease market is dominated by the hospital pharmacy segment. The senior population's rise, high hospitalization rates, and the severity of dry eye disease are predicted to fuel the segment's expansion. Conversely, the market for treatments for Dry Eye Disease was dominated by the retail pharmacy sector, which had the second-largest share.

For a better understanding of the market adoption of Dry Eye Disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2023. This dominance can be attributed to several factors that drive the demand and development of dry eye disease therapeutics in the region, such as high disposable income, advanced healthcare infrastructure, and rising awareness. Some of the major players operating in the market include AbbVie Inc, Alcon Inc., Akorn, Johnson & Johnson, Bausch Health Companies Inc., Horus Pharma, Mitotech, Novaliq GmbH, OASIS Medical, and Otsuka Pharmaceutical Co. Ltd.

1.MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Dry Eye Disease Market
2.2. Research Methodology of the Dry Eye Disease Market
2.3. Respondent Profile

3.EXECUTIVE SUMMARY

3.1. Industry Synopsis
3.2. Segmental Outlook
- 3.2.1. Market Growth Intensity
3.3. Regional Outlook

4.MARKET DYNAMICS

4.1. Drivers
4.2. Opportunity
4.3. Restraints
4.4. Trends
4.5. PESTEL Analysis
4.6. Demand Side Analysis
4.7. Supply Side Analysis
- 4.7.1. Merger & Acquisition
- 4.7.2. Investment Scenario
- 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

5.1. Regional Pricing Analysis
5.2. Price Influencing Factors

6.GLOBAL DRY EYE DISEASE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET SEGMENT BY PRODUCT

7.1. Artificial Tears
7.2. Anti-inflammatory Drugs
7.3. Punctal Plugs
7.4. Secretagogues
7.5. Other Products

8.MARKET SEGMENT BY DISTRIBUTION CHANNEL

8.1. Hospital Pharmacy
8.2. Retail Pharmacy
8.3. Online Pharmacy

9.MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World

10.VALUE CHAIN ANALYSIS

10.1. List of Market Participants

11.COMPETITIVE LANDSCAPE

11.1. Competition Dashboard
11.2. Competitor Market Positioning Analysis
11.3. Porter Five Forces Analysis

12.COMPANY PROFILED

12.1. AbbVie Inc
- 12.1.1. Company Overview
- 12.1.2. Key Financials
- 12.1.3. SWOT Analysis
- 12.1.4. Product Portfolio
- 12.1.5. Recent Developments
12.2. Alcon Inc.
12.3. Akorn
12.4. Johnson & Johnson
12.5. Bausch Health Companies Inc.
12.6. Horus Pharma
12.7. Mitotech
12.8. Novaliq GmbH
12.9. OASIS Medical
12.10. Otsuka Pharmaceutical Co. Ltd